Gilead Sciences GILD Odefsey — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's odefsey — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's odefsey — total revenues?
- Gilead Sciences (GILD) reported odefsey — total revenues of $221M in Q1 2026.
- How has Gilead Sciences's odefsey — total revenues changed year-over-year?
- Gilead Sciences's odefsey — total revenues decreased by 21.4% year-over-year, from $281M to $221M.
- What is the long-term trend for Gilead Sciences's odefsey — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's odefsey — total revenues has grown at a -7.1% compound annual growth rate (CAGR), from $1.57B to $1.17B.
- What does odefsey — total revenues mean?
- The total revenue generated by the sale of a specific HIV medication product line.
- How do you interpret odefsey — total revenues?
- An increase indicates growing market adoption or successful patient retention for this specific therapy, while a decrease may signal increased competition, patent expiration, or a shift in clinical treatment guidelines.
- How does odefsey — total revenues compare across companies?
- Comparable to product-level revenue reporting in other major biopharmaceutical companies, often benchmarked against similar therapeutic area franchises like HIV or oncology portfolios.